Is Abbott India a Good Buy After Its Q1 FY27 Results?
- September 2, 2026
- Posted by: Kunal Singla
- Category: Market
Abbott India share price around Rs 26,135. 20.3% below 52-week high of Rs 32,775. Q1 FY27 revenue Rs 1,814 crore, up 4.3% YoY. PAT Rs 429 crore, up 17.1%. PE 34x.
Quick Answer
Abbott India’s Q1 FY27 results were strong, with revenue at Rs 1,814 crore and PAT climbing 17% to Rs 429 crore. The stock trades at a PE of 34x against an industry average near 51x, which leaves room for a re-rating if this growth continues. The Abbott India share price near Rs 26,135 reflects that optimism, so investors weighing whether Abbott India is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.
The Abbott India share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Abbott India is a pharmaceutical major selling branded generics, nutrition and consumer health products, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 1,814 crore, up 4.3% year on year, while profit after tax came in at Rs 429 crore, up 17.1% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Abbott India share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Abbott India share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Abbott India Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 1,814 crore | Rs 1,738 crore | 4.3% |
| Profit Before Tax | Rs 572 crore | NA | NA |
| Net Profit / (Loss) | Rs 429 crore | Rs 366 crore | 17.1% |
Abbott India Q1 FY27 Performance Analysis
Check Abbott India Fundamentals on Univest Screener
Revenue growth of 4.3% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmaceuticals sector.
The bigger story is on profitability. PAT grew 17% to Rs 429 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the Abbott India share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.
Sequential quarterly data was not fully available for this comparison, so investors should track the next quarter’s results to build out the trend behind the Abbott India share price.
Key Business Factors in Q1 FY27
Revenue Trend
Abbott India’s revenue grew 4.3% year on year this quarter, taking the quarterly base to Rs 1,814 crore in a pharmaceuticals business that remains sensitive to demand and pricing cycles that ultimately feed through to the Abbott India share price.
Profitability Trend
Profit before tax came in at Rs 572 crore for the quarter, a figure worth tracking alongside the headline PAT number for a fuller picture of the quarter.
Balance Sheet Position
Abbott India carries a low debt-to-equity ratio of 0.04, giving it a conservative balance sheet heading into the rest of FY27.
Valuation Context
The stock trades at a PE of 34.0x, below the industry average of 51.4x, which is worth factoring into any read of whether the Abbott India share price is expensive or reasonably priced.
Dividend Details
No interim dividend was declared alongside Abbott India’s Q1 FY27 results. The stock currently carries a trailing dividend yield of 2.54%, based on dividends paid over the last year. Investors tracking the Abbott India share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Abbott India Share Price Outlook for FY27
The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Abbott India can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter’s momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.
For the Abbott India share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter’s pace, since any slowdown would put pressure on a stock priced for continued strength.
Abbott India Stock Performance
Download the Univest iOS App or Univest Android App to track Abbott India’s live share price and get daily stock updates.
The Abbott India share price was trading around Rs 26,135 as results season played out in late August 2026, roughly 20.3% below its 52-week high of Rs 32,775 and well above its 52-week low of Rs 25,150. Promoter holding stood at 75.0% as of the June 2026 quarter.
The Abbott India share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 32.51% and a book value of around Rs 2,247 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Sector and Demand Risk
As a pharmaceuticals business, Abbott India’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Abbott India share price well before the next result.
Execution Risk
Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
Conclusion
Abbott India’s Q1 FY27 results were genuinely strong, with revenue at Rs 1,814 crore and PAT up 17% to Rs 429 crore. That said, at a PE of 34.0x, the Abbott India share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Abbott India is a good buy should weigh the strong quarter against the valuation before adding at current levels.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Abbott India Q1 FY27 Results
What were Abbott India’s Q1 FY27 results?
Ans. Abbott India reported Q1 FY27 revenue of Rs 1,814 crore, up 4.3% year on year, and PAT of Rs 429 crore, up 17.1% year on year.
Is Abbott India a good buy after its Q1 FY27 results?
Ans. Abbott India’s core numbers improved this quarter, though at a PE of 34.0x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.
What is the Abbott India share price today?
Ans. The Abbott India share price was trading around Rs 26,135 in late August 2026, about 20.3% below its 52-week high of Rs 32,775 and well above its 52-week low of Rs 25,150.
What is Abbott India’s revenue and profit for Q1 FY27?
Ans. Abbott India reported revenue of Rs 1,814 crore and a net profit of Rs 429 crore for the quarter ended June 30, 2026.
Did Abbott India declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Abbott India’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Abbott India’s PE ratio and is it expensive?
Ans. The Abbott India share price trades at a trailing PE of 34.0x, against an industry average of 51.4x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Abbott India investors right now?
Ans. As a pharmaceuticals business, Abbott India’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Abbott India share price well before the next result. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
What is Abbott India’s promoter shareholding?
Ans. Promoter holding in Abbott India stood at 75.0% as of the June 2026 quarter.
